Financial Performance
Global Health Limited (Medanta) reported strong financial results for FY 2025-26 with consolidated revenue growing 19.6% to ₹45,089 million and profit after tax increasing 15.1% to ₹5,541 million. Standalone revenue reached ₹37,094 million (15.8% growth) with net profit of ₹4,962 million. The company maintained robust liquidity with ₹5,906 million net cash position and generated ₹7,144 million in operating cash flow.
Operational Metrics
Medanta expanded to 3,665 beds across six hospitals, adding 623 beds including the new Noida hospital. Key operational highlights include 202,112 inpatient volumes (16.0% growth), 3,485,997 outpatient encounters (18.7% growth), and international patient revenues of ₹2,780 million (33.2% growth). The company achieved clinical milestones with Medanta Gurugram ranked #1 hospital in India by Newsweek for the 7th consecutive year.
Expansion and Capex
The company has an aggressive expansion pipeline of ~3,350 additional beds across Mumbai (~750 beds), Pitampura (~750 beds), South Delhi (~400 beds), Guwahati (650 beds), and Varanasi (400 beds) with estimated capex of ~₹48,500 million over the next 5 years. Current capital work-in-progress stands at ₹1,322 million with additional borrowings of ₹6,311 million raised for project financing.
ESG and Sustainability
Medanta submitted comprehensive BRSR Core sustainability reporting covering environmental metrics including Scope 1 emissions (5,006.55 MT CO2e), Scope 2 emissions (41,059.44 MT CO2e), water consumption (598,777.55 KL), and waste management (3,033.59 metric tonnes). Social highlights include 100% accessibility compliance, 94% return-to-work post parental leave, and 29% of wages paid to female employees, with assurance provided by SGS India.
Corporate Actions and Governance
The board recommended a 25% dividend (₹0.50 per share) with record date of August 14, 2026 and AGM scheduled for September 16, 2026. The auditor issued unqualified opinions on both financial statements and internal financial controls, confirming adequate governance frameworks. The company maintains strong compliance with SEBI regulations and Companies Act requirements.
Subsidiary Performance and Structure
Key subsidiaries include Global Health Patliputra Private Limited (material subsidiary), GHL Pharma & Diagnostic Private Limited, GHL Hospital Limited, and Global Health Institute of Medical Sciences Foundation. The consolidated entity shows strong performance across all subsidiaries with total assets of ₹59,050 million and equity of ₹39,843 million as of March 31, 2026.